REFERENCES

- [1] Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. *Expert Opin Drug Saf.* 2016;15:457-65
- Disclosure of Interests:** None declared
- DOI:** 10.1136/annrheumdis-2019-eular.7846

SLE, Sjögren's and APS – treatment

AB0457

AUDIT ON HYDROXYCHLOROQUINE RELATED RETINOPATHY SCREENING IN RHEUMATOLOGY PATIENTS IN SVUH

Aadil Al Ghafr, Eamonn S. Molloy. *St Vincent's University Hospital, Rheumatology, Dublin, Ireland*

Background: Hydroxychloroquine (HCQ) is a medication commonly used to treat rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other rheumatological conditions. A known adverse effect associated with long-term use of these medications is vision loss resulting from irreversible retinal toxic effects. Recent guidelines emphasized on routine ophthalmological examination and to adhere on real weight-based dosages.

Objectives: This audit conducted to evaluate adherence rate on standard recommendation on HCQ related retinopathy screening in rheumatology patients in St Vincent's University Hospital (SVUH).

Methods: Patient were on HCQ and attended rheumatology clinics at SVUH with rheumatic diseases selected randomly from on 01/08/2017 and end on 01/04/2018. A total sample size of 56 patients received a questionnaire that included information on HCQ dose, duration and actual body weight. Other information included precipitant factors and ophthalmology examination reports were retrieved retrospectively from patient's chart. Standards were measured against recommendations on screening for HCQ retinopathy published by American Academy of Ophthalmology, 2016 Revision.

Results: Total 56 patients on HCQ with different rheumatic disease studied. Out of 56 patients studied, 6/56 (10.7%) were <25 years (young), 45/56 (80.4%) were 25-65 years (middle age), and 5/56 (8.9%) were >65 years (elderly). Sex distribution showed that 7/56 (12.5%) were males and 49/56 (87.5%) were females. Around 35.7% (20/56) were in HCQ dose >5mg/kg, and 64.3% (36/56) were on standard HCQ dose (<=5mg/kg of real body weight. The were 44.6% (25/54) patients on HCQ for a period <5 years, the rest, 55.4% (32/56) were on HCQ for a period of 5-20years, and none of these patients were on it for >20 years duration. There were only 1/56 (1.8%) patient with history of HCQ toxicity, 98.2% (55/56) showed no history of HCQ related toxicity. None of the 56 patients had any of the following influencing factors: renal impairment, Tamoxifen usage, coagulopathies, hepatic impairment, or pre-existing retinal/maculular disease. However, there were 8.9% (5/56) of this group their age was > 65years (verses 51/56 91.1% were <65years age. Only 69.6% (39/56) of these patients underwent retinal baseline screening, were 17/56 (30.4%) did not receive any baseline screening after commencing HCQ therapy. Frequency of follow up retinal screening were done annually in 19/56 (33.9%), 5 yearly in 6/56 (10.7%). However, it was not done in 21/56 (37%) and it was not due in 9/56 (16.1%). Out of those who underwent the screening at any time, 32/56 (57.1%) showed normal examination results, only 1/56 patient (1.8%) showed abnormal results. Rest of the patient data either were not available, or examination were not done.

Conclusion: Above data emphases the need to adhere on standards HCQ retinal screening as baseline and follow up. Furthermore, adherence on real weight calculated dose rather than estimated/average body weight.

REFERENCES

- [1] -Michael F. Marmor, Ulrich Kellner, Timothy Y.Y. Lai, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). *Ophthalmology.* 2017 Mar;124(3):e28-e29.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.196

AB0458

A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS)

Maria Juarez¹, Nieves Diaz¹, Geoffrey I. Johnston¹, Saba Nayar², Andrew Payne¹, Eric Helmer¹, Dionne Cain¹, Paulette Williams³, Wan Fai Ng⁴, Benjamin Fisher², Jacques-Eric Gottenberg⁵, Giuliana Guggino⁶, Xavier Mariette⁷, Marika Kvarnström⁸, Valerie Devauchelle-Pensec⁹, Jose Rosas¹⁰, Juan Sanchez-Burson¹¹, Roberto Giacomelli¹², Francesca Barone², Simon J. Bowman¹³. ¹UCB Pharma, Slough, United Kingdom; ²University of Birmingham, Birmingham, United Kingdom; ³UCB Pharma, Raleigh, United States of America; ⁴Newcastle University and NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, United Kingdom; ⁵Strasbourg University Hospital, Strasbourg, France; ⁶University of Palermo, Palermo, Italy; ⁷Université Paris-Sud, Paris, France; ⁸Karolinska Institutet, Stockholm, Sweden; ⁹Cavale Blanche Hospital, Brest, France; ¹⁰Hospital Marina Baixa, Villajoyosa, Spain; ¹¹Infantluisa Hospital, Sevilla, Spain; ¹²University of L'Aquila, L'Aquila, Italy; ¹³University Hospitals and Birmingham Biomedical Research Centre, Birmingham, United Kingdom

Background: Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease pathogenesis.¹

Objectives: To assess the efficacy and safety of seletalisib in patients with PSS.

Methods: In this Phase II, double-blind, proof of concept study (NCT02610543), patients with PSS having an EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score ≥5 were randomised 1:1 to seletalisib once daily or placebo (PBO) in addition to current PSS therapy for 12 weeks. The primary endpoint was change from baseline in ESSDAI at Week 12. The study was designed to have 80% power to detect a difference of 3.8 points in change from baseline in ESSDAI between seletalisib and PBO at Week 12 and required 58 patients to complete treatment. Other endpoints included EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), salivary gland biopsy changes, Schirmer's I test, immunoglobulin concentrations and incidence of treatment-emergent adverse events (TEAEs).

Table 1. Change from baseline to Week 12 for secondary and exploratory endpoints (full analysis set)

	Seletalisib n=13, LS mean (SE)	PBO n=14, LS mean (SE)	Difference (95% CI)
ESSPRI score ^a	-2.13 (0.68)	-0.57 (0.56)	-1.55 (-3.39, 0.28)
Stimulated salivary flow rate, mL/min ^a	-0.08 (0.11)	-0.11 (0.08)	0.02 (-0.27, 0.31)
Schirmer's I test score ^b	-0.9 (3.3)	0.5 (2.6)	-1.41 (-10.35, 7.52)
Immunoglobulin G, g/L ^a	-2.36 (0.71)	1.17 (0.64)	-3.53 (-5.55, -1.51)
Immunoglobulin M, g/L ^a	-0.33 (0.10)	0.07 (0.09)	-0.40 (-0.68, -0.12)
Immunoglobulin A, g/L ^a	0.03 (0.13)	0.06 (0.12)	-0.03 (-0.40, 0.34)

LS, least squares; SE, standard error

^a Mixed model for repeated measures analysis

^b Analysis of covariance

Results: The study was terminated early due to slow recruitment, which led to study power decreasing to 36%. Twenty of 27 patients randomised (seletalisib n=13, PBO n=14) completed treatment. Demographic characteristics were generally similar between groups. Mean (SE) change from baseline in ESSDAI at Week 12 was seletalisib -5.4 (1.7) vs PBO -2.8 (1.5); treatment difference vs PBO (95% CI) was -2.59 (-7.30, 2.11; p=0.266). The percentages of patients achieving a ≥3 point reduction in ESSDAI were seletalisib 66.7% vs PBO 54.5%. Post-hoc Bayesian analyses of treatment difference showed an 86.5% probability of being superior to PBO and a 48.8% probability of a >3 point difference from PBO. Clinically notable improvements in some secondary endpoints were also observed in the seletalisib group (Table 1). Minor salivary gland biopsies had broadly similar histological features across groups at baseline. At